Fleisch J H, Armstrong C T, Roman C R, Mihelich E D, Spaethe S M, Jackson W T, Bobbitt J L, Draheim S, Bach N J, Dillard R D, Martinelli M, Fouts R, Snyder D W
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.
J Pharmacol Exp Ther. 1996 Jul;278(1):252-7.
The primary objective of this study was to develop a functional assay that could provide rapid and reliable information on some pharmacologic characteristics of a novel inhibitor of human secretory phospholipase A2 (sPLA2). Guinea pig bronchoalveolar lavage (BAL) fluid, containing predominantly macrophages, eosinophils and epithelial cells, released thromboxane A2, as measured by thromboxane B2, in a concentration-dependent manner on exposure to recombinant human sPLA2 (rh-sPLA2). Similarly, n-formyl-L-methionyl-L-leucyl-L-phenylalanine (n-F-Met-Leu-Phe) or arachidonic acid also released this lipid mediator. Indomethacin, a cyclooxygenase inhibitor, blocked synthesis of thromboxane in response to these agents. p-Bromophenacylbromide-inactivated rh-sPLA2 was substantially less effective than the untreated enzyme in causing release of thromboxane. LY311727 is a potent indole-derived inhibitor of the isolated enzyme (IC50 = 23 nM). Incubation of this agent with BAL cells, just before addition of rh-sPLA2, reduced release of thromboxane with an IC50 = 1.8 x 10(-6) M. Specificity for sPLA2 was demonstrated in that LY311727, unlike indomethacin, did not reduce synthesis and subsequent release of thromboxane A2 in response to arachidonic acid. Using this technique as a basis, we determined whether LY311727 could sufficiently accumulate in lung after i.v. administration to inhibit rh-sPLA2-induced thromboxane A2 release from BAL cells. The compound, given i.v. to guinea pigs 5 min before collecting BAL fluid, produced a dose-dependent inhibition of rh-sPLA2 with an ED50 = 50 mg/kg. Thus, new in vitro and ex vivo assays were developed that permit functional evaluation of novel sPLA2 inhibitors. These techniques should serve as secondary assays for evaluation of human sPLA2 inhibitory activity from a chemical series and in addition provide initial data related to metabolic stability and distribution to the lung.
本研究的主要目的是开发一种功能测定方法,该方法可以提供有关新型人分泌型磷脂酶A2(sPLA2)抑制剂某些药理学特性的快速且可靠的信息。豚鼠支气管肺泡灌洗(BAL)液主要包含巨噬细胞、嗜酸性粒细胞和上皮细胞,在暴露于重组人sPLA2(rh-sPLA2)时,以浓度依赖性方式释放血栓素A2(通过血栓素B2测量)。同样,N-甲酰-L-蛋氨酰-L-亮氨酰-L-苯丙氨酸(n-F-Met-Leu-Phe)或花生四烯酸也能释放这种脂质介质。环氧化酶抑制剂吲哚美辛可阻断这些物质诱导的血栓素合成。对溴苯甲酰溴灭活的rh-sPLA2在引起血栓素释放方面比未处理的酶效果要差得多。LY311727是一种对分离出的酶有强效抑制作用的吲哚衍生物(IC50 = 23 nM)。在加入rh-sPLA2之前,将该药物与BAL细胞一起孵育,可减少血栓素的释放,IC50 = 1.8×10⁻⁶ M。LY311727对sPLA2具有特异性,因为与吲哚美辛不同,它不会降低因花生四烯酸而导致的血栓素A2的合成及随后的释放。以该技术为基础,我们测定了静脉注射LY311727后,它是否能在肺中充分蓄积以抑制rh-sPLA2诱导的BAL细胞释放血栓素A2。在收集BAL液前5分钟给豚鼠静脉注射该化合物,可产生对rh-sPLA2的剂量依赖性抑制作用,ED50 = 50 mg/kg。因此,开发了新的体外和离体测定方法,可对新型sPLA2抑制剂进行功能评估。这些技术应用于评估化学系列中人sPLA2抑制活性的二级测定,此外还可提供与代谢稳定性及肺分布相关的初始数据。